clinical trial · NCT05552976
A Study to Evaluate Mezigdomide in Combination With Carfilzomib and Dexamethasone (MeziKD) Versus Carfilzomib and Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma (SUCCESSOR-2)
Bristol-Myers Squibb·phase3·active not recruiting·n = 606
Relapsed or Refractory Multiple MyelomaMezigdomideCarfilzomibDexamethasone
brief summary
The purpose of the study is to compare Mezigdomide (CC-92480/BMS-986348) with carfilzomib and dexamethasone (MeziKD) against carfilzomib and dexamethasone (Kd) in the treatment of RRMM: SUCCESSOR-2.
started
Jan 10, 2023
primary completion
Jul 18, 2026
completion
Jul 25, 2029
last updated
Apr 1, 2026
official title
A Phase 3, Two-stage, Randomized, Multicenter, Open-label Study Comparing Mezigdomide (CC-92480/BMS-986348), Carfilzomib, and Dexamethasone (MeziKD) Versus Carfilzomib and Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM): SUCCESSOR-2
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol